Detection of urine circulating tumor DNA using droplet digital PCR for predicting hepatocellular carcinoma recurrence

Abstract

Aim: This study aims to evaluate the feasibility of examining circulating tumor DNA (ctDNA) in urine samples from hepatocellular carcinoma (HCC) patients by droplet digital PCR (ddPCR) and to assess its value in predicting HCC recurrence after surgery.

Methods: HCC cases who accepted surgical resection were included. Perioperative urine, tissue and peripheral blood specimens were collected. Four hotspot mutants [TP53-rs28934571 (c.747G>T), TRET-rs1242535815 (c.1-124C>T), CTNNB1-rs121913412 (c.121A>G), and CTNNB1-rs121913407 (c.133T>C)] were chosen for ctDNA analysis, and mutant allele frequency (MAF) was worked out. Sanger sequencing was performed on matched tumor tissues and peripheral blood mononuclear cells (PBMCs). The patients’ clinicopathologic characteristics were retrospectively analyzed. The predictive abilities of urine ctDNA for postoperative recurrence were evaluated using the Kaplan-Meier method.

Results: Forty-six patients were enrolled, and 18 patients (39.1%, 18/46) exhibited detectable circulating mutants, with the MAF in the range of 0.07% to 0.91%. The consistency test indicated moderate to substantial concordance between urine and paired tumor tissue mutations. The mutation level dropped dramatically or disappeared after surgery. Positive urine ctDNA before surgery was closely related to greater tumor size and recurrence. Kaplan-Meier curves revealed significantly shorter disease-free survival (DFS) for ctDNA-positive patients. Multivariate analysis identified detectable urine ctDNA as an independent risk factor for tumor recurrence. More than that, receiver operating characteristic (ROC) curves demonstrated that urine ctDNA had the largest area under the curve (AUC) for predicting HCC recurrence.

Conclusion: Detecting ctDNA in urine using ddPCR is feasible and holds significant potential for predicting and monitoring HCC recurrence.

Keywords

Urine / ctDNA / hepatocellular carcinoma / recurrence

References

[1] Vogel A,Sapisochin G,Saborowski A.Hepatocellular carcinoma.Lancet2022;400:1345-62

[2] Ye Q,Zheng S.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.Mol Cancer2019;18:114 PMCID:PMC6607541

[3] Colombo F,Mazzucchelli S.Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.PLoS One2011;6:e21369 PMCID:PMC3121782

[4] Zhou J,Wang Z.Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition).Liver Cancer2023;12:405-44 PMCID:PMC10601883

[5] Siravegna G,Siena S.Integrating liquid biopsies into the management of cancer.Nat Rev Clin Oncol2017;14:531-48

[6] Luo P,Yu Y.Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage.Pathol Oncol Res2020;26:599-603

[7] Trevisani F,Morselli-Labate AM.Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.J Hepatol2001;34:570-5

[8] Cui R,Zhang F.Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein.Br J Cancer2003;88:1878-82 PMCID:PMC2741121

[9] Hann HW,Park G,Song W.Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.Hepatoma Res2017;3:105-11 PMCID:PMC5546802

[10] Diaz LA Jr.Liquid biopsies: genotyping circulating tumor DNA.J Clin Oncol2014;32:579-86 PMCID:PMC4820760

[11] Bettegowda C,Leary RJ.Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[12] Chan KC,Woo JK.Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.Cancer2013;119:1838-44

[13] Campitelli M,Peter M.Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients.PLoS One2012;7:e43393 PMCID:PMC3427328

[14] Huang A,Zhou SL.Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity.J Cancer2016;7:1907-14 PMCID:PMC5039376

[15] Wang J,Wang YP.Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma.Ann Transl Med2020;8:237 PMCID:PMC7154404

[16] Abdullaev SA,Bezlepkin VG.Cell-free DNA in the urine of rats exposed to ionizing radiation.Radiat Environ Biophys2015;54:297-304

[17] Chen S,Cui L.Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.Clin Transl Oncol2017;19:332-40

[18] Husain H,Kosco K.Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine.Clin Cancer Res2017;23:4716-23 PMCID:PMC5737735

[19] Karachaliou N, Mayo-de las Casas C, Queralt C, et al; Spanish Lung Cancer Group. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 2015;1:149-57.

[20] Tivey A,Rothwell D,Cook N.Circulating tumour DNA - looking beyond the blood.Nat Rev Clin Oncol2022;19:600-12 PMCID:PMC9341152

[21] Augustus E,Sorber L.The art of obtaining a high yield of cell-free DNA from urine.PLoS One2020;15:e0231058 PMCID:PMC7135229

[22] Green EA,Albiges L.Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: a critical review of current literature.Eur Urol Oncol2021;4:893-903

[23] Mouliere F,Arnau Peyrotte E.High fragmentation characterizes tumour-derived circulating DNA.PLoS One2011;6:e23418 PMCID:PMC3167805

[24] Hindson BJ,Masquelier DA.High-throughput droplet digital PCR system for absolute quantitation of DNA copy number.Anal Chem2011;83:8604-10 PMCID:PMC3216358

[25] Taly V,Benhaim L.Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.Clin Chem2013;59:1722-31

[26] Hinohara K.Intratumoral heterogeneity: more than just mutations.Trends Cell Biol2019;29:569-79 PMCID:PMC6579620

[27] Pribluda A,Jackson EL.Intratumoral heterogeneity: from diversity comes resistance.Clin Cancer Res2015;21:2916-23

[28] De Mattos-Arruda L,Cortes J.Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.Ann Oncol2018;29:2268 PMCID:PMC6887917

[29] Pantel K.Liquid biopsy and minimal residual disease - latest advances and implications for cure.Nat Rev Clin Oncol2019;16:409-24

[30] Head SR,LaMere SA.Library construction for next-generation sequencing: overviews and challenges.Biotechniques2014;56:61-4,66,68, passim PMCID:PMC4351865